Incyte Corporation
INCYNext catalyst
Povorcitinib
NonSegmental Vitiligo
Get an email about INCY's next catalysts
Track Incyte (INCY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 26 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline
27 upcoming, 4 past
povorcitinib Phase 2 Est. Readout
Estimated primary completion for povorcitinib trial (NCT05851443) in Moderate to Severe Asthma. Topline data typically follows completion by weeks to months.
SourceAxatilimab Phase 2 Est. Readout (NAHL)
Estimated primary completion for Axatilimab trial (NCT05723055) in Hodgkin Lymphoma. Topline data typically follows completion by weeks to months.
SourcePovorcitinib Phase 3 Est. Readout (STOP-HS LTE)
Estimated primary completion for Povorcitinib trial (NCT06212999) in Hidradenitis Suppurativa (HS). Topline data typically follows completion by weeks to months.
SourceTafasitamab Phase 2 Est. Readout
Estimated primary completion for Tafasitamab trial (NCT05351593) in CNS Lymphoma. Topline data typically follows completion by weeks to months.
SourceRuxolitinib Phase 2 Est. Readout
Estimated primary completion for Ruxolitinib trial (NCT06345495) in Splenomegaly. Topline data typically follows completion by weeks to months.
SourceINCA034176 Phase 2 Est. Readout
Estimated primary completion for INCA034176 trial (NCT06843408) in Chronic Graft-versus-host-disease. Topline data typically follows completion by weeks to months.
SourceTafasitamab Phase 2 Est. Readout
Estimated primary completion for Tafasitamab trial (NCT06760156) in Large B-cell Lymphoma. Topline data typically follows completion by weeks to months.
SourceRetifanlimab Phase 2 Est. Readout (TRICK-MCC)
Estimated primary completion for Retifanlimab trial (NCT06056895) in Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8. Topline data typically follows completion by weeks to months.
SourceHow INCY's past catalysts played out
Market Overview
Stock performance and key metrics
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
WebsiteRetifanlimab
Metastatic Merkel Cell Carcinoma
Tafasitamab
Diffuse Large B Cell Lymphoma
Extracorporeal photopheresis (ECP)
Graft-versus-host Disease (GVHD)
Povorcitinib
NonSegmental Vitiligo
Topical corticosteroid
Atopic Dermatitis
ruxolitinib tablets
Polycythemia Vera
Mercaptopurine
Leukemia
Corticosteroids
Chronic Graft-versus-host-disease
Thioguanine
Leukemia
Bendamustine (BEN)
Diffuse Large B-cell Lymphoma
INCB123667
Ovarian Cancer
INCA034176
Chronic Graft-versus-host-disease
INCA33890
CRC (Colorectal Cancer)
INCB161734
Solid Tumors
Hydroxyurea (HU)
Polycythemia Vera
Itacitinib
MPN (Myeloproliferative Neoplasms)
Ruxolitinib
MPN (Myeloproliferative Neoplasms)
pembrolizumab + epacadostat
Melanoma
INCA033989
Essential Thrombocythemia
Tacrolimus (Tac)
Graft-versus-host Disease (GVHD)
Epacadostat
Lung Cancer
Best Available Treatment
Essential Thrombocythemia
Ruxolitinib Cream
Nonsegmental Vitiligo With Genital Involvement
Baricitinib
Alopecia Areata
Calaspargase Pegol
Acute Lymphoblastic Leukemia
Ruxolitinib (Rux)
Graft-versus-host Disease (GVHD)
Asparaginase Erwinia chrysanthemi (recombinant)-rywn
Acute Lymphoblastic Leukemia
Erwinase®
Acute Lymphoblastic Leukemia
Nelarabine
Acute Lymphoblastic Leukemia
Supportive Care: Seizure prophylaxis
AML (Acute Myelogenous Leukemia)
Post-transplant Abatacept
AML (Acute Myelogenous Leukemia)
Supportive Care: Prophylaxis against infections
AML (Acute Myelogenous Leukemia)
All-trans retinoic acid
Glioma
Conditioning Regimen A
AML (Acute Myelogenous Leukemia)
Conditioning Regimen E
AML (Acute Myelogenous Leukemia)
BCR-ABL Tyrosine Kinase Inhibitor (TKI)
Chronic Phase Chronic Myeloid Leukemia
Post-transplant Ruxolitinib
AML (Acute Myelogenous Leukemia)
Conditioning Regimen B
AML (Acute Myelogenous Leukemia)
PTCy (D3, D4)
AML (Acute Myelogenous Leukemia)
Conditioning Regimen C
AML (Acute Myelogenous Leukemia)
Conditioning Regimen D
AML (Acute Myelogenous Leukemia)
Post-transplant Tacrolimus
AML (Acute Myelogenous Leukemia)
Supportive Care: Growth Factors
AML (Acute Myelogenous Leukemia)
INCA000585
Immune Thrombocytopenia
INCB024360
Myelodysplastic Syndromes
INCMGA00012 (PD-1 antibody)
Pancreatic Cancer Non-resectable
Yescarta
Cytokine Release Syndrome
MELITAC 12.1 Peptide Vaccine
Mucosal Melanoma
INCAGN01876
Advanced Malignancies
GVAX Pancreas Vaccine
Metastatic Pancreatic Adenocarcinoma
INCAGN01949
Advanced Malignancies
R-CHOP
Non Hodgkins Lymphoma
Pelareorep
Anatomic Stage IV Breast Cancer AJCC v8
Ulixertinib
Myelofibrosis
Axatilimab (SNDX-6352)
Myelofibrosis (MF)
INCMGA00012
Resectable Sarcoma
SRS
Glioblastoma
Tuparstobart
Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8
Donor Lymphocyte Infusion (DLI)
Acute Myeloid Leukemia
Verzistobart
Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8
Dovonex® calcipotriene
Psoriasis
Ruxolitinib Topical Cream
Exanthema
Pegaspargase
Leukemia
Vincristine Sulfate
Leukemia
Diprolene® AF betamethasone dipropionate cream
Psoriasis
Myeloablative conditioning regimen
Leukemia
CAPOX chemotherapy
Rectal Cancer
FOLFOX chemotherapy
Rectal Cancer
parsaclisib + ruxolitinib
B-Cell Malignancies
parsaclisib + ibrutinib
B-Cell Malignancies
Epcoritamab, tafasitamab and lenalidomide
Large B Cell Lymphoma
Granulocyte Colony-Stimulating Factor
Aplastic Anemia
JAK Inhibitor
Myelodysplastic/Myeloproliferative Neoplasm
topical ruxolitinib
Pyoderma Gangrenosum
Chimeric antigen receptor (CAR) T-cell therapy
Diffuse Large B Cell Lymphoma
INCB001158
Biliary Tract Cancer (BTC)
INCB177054
Solid Tumors
ICS-LABA
Moderate to Severe Asthma
Pemigatinib
Non-Small Cell Lung Cancer (NSCLC)
Asparaginase Erwinia Chrysanthemi
Leukemia
INCB013739
Type 2 Diabetes
INCB000928
Anemia
Ruxolitinib phosphate cream
Psoriasis
INCB054707
Hidradenitis Suppurativa
Parsaclisib
B-Cell Malignancies
Ponatinib
Philadelphia Positive
INCB009471
HIV Infections
INCB099280
Advanced Solid Tumor
INCAGN02385
Endometrial Cancer
Axatilimab
Chronic Graft-versus-host-disease
INCAGN02390
Melanoma
Best available Treatment (BAT)
Chronic Graft-versus-host-disease
INCB018424
Rheumatoid Arthritis
INCB028050
Rheumatoid Arthritis
Prednisone or methylprednisolone
Graft-versus-host Disease (GVHD)
Ruxolitinib Phosphate
Psoriasis
Immune effector cell therapy
Cytokine Release Syndrome
Platinum-based chemotherapy
Lung Cancer
parsaclisib + itacitinib
B-Cell Malignancies
MEDI4736
Solid Tumors
Regorafenib
Pancreatic Cancer
MK-3475
Microsatellite-instability (MSI) High Colorectal Cancer (CRC)
Post-transplant Mycophenolate mofetil
AML (Acute Myelogenous Leukemia)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Retifanlimab | Phase 3 | Metastatic Merkel Cell Carcinoma | - | - |
Tafasitamab | Phase 3 | Diffuse Large B Cell Lymphoma | - | - |
Extracorporeal photopheresis (ECP) | Phase 3 | Graft-versus-host Disease (GVHD) | - | - |
Povorcitinib | Phase 3 | NonSegmental Vitiligo | - | - |
Topical corticosteroid | Phase 3 | Atopic Dermatitis | - | - |
ruxolitinib tablets | Phase 3 | Polycythemia Vera | - | - |
Mercaptopurine | Phase 3 | Leukemia | - | - |
Corticosteroids | Phase 3 | Chronic Graft-versus-host-disease | - | - |
Thioguanine | Phase 3 | Leukemia | - | - |
Bendamustine (BEN) | Phase 3 | Diffuse Large B-cell Lymphoma | - | - |
INCB123667 | Phase 3 | Ovarian Cancer | - | - |
INCA034176 | Phase 3 | Chronic Graft-versus-host-disease | - | - |
INCA33890 | Phase 3 | CRC (Colorectal Cancer) | - | - |
INCB161734 | Phase 3 | Solid Tumors | - | - |
Hydroxyurea (HU) | Phase 3 | Polycythemia Vera | - | - |
Itacitinib | Phase 3 | MPN (Myeloproliferative Neoplasms) | - | - |
Ruxolitinib | Phase 3 | MPN (Myeloproliferative Neoplasms) | - | Patent 2041 |
pembrolizumab + epacadostat | Phase 3 | Melanoma | - | - |
INCA033989 | Phase 3 | Essential Thrombocythemia | - | - |
Tacrolimus (Tac) | Phase 3 | Graft-versus-host Disease (GVHD) | - | - |
Epacadostat | Phase 3 | Lung Cancer | - | - |
Best Available Treatment | Phase 3 | Essential Thrombocythemia | - | - |
Ruxolitinib Cream | Phase 3 | Nonsegmental Vitiligo With Genital Involvement | - | - |
Baricitinib | Phase 3 | Alopecia Areata | - | - |
Calaspargase Pegol | Phase 3 | Acute Lymphoblastic Leukemia | - | - |
Ruxolitinib (Rux) | Phase 3 | Graft-versus-host Disease (GVHD) | - | - |
Asparaginase Erwinia chrysanthemi (recombinant)-rywn | Phase 3 | Acute Lymphoblastic Leukemia | - | - |
Erwinase® | Phase 3 | Acute Lymphoblastic Leukemia | - | - |
Nelarabine | Phase 3 | Acute Lymphoblastic Leukemia | - | - |
Supportive Care: Seizure prophylaxis | Phase 2 | AML (Acute Myelogenous Leukemia) | - | - |
Post-transplant Abatacept | Phase 2 | AML (Acute Myelogenous Leukemia) | - | - |
Supportive Care: Prophylaxis against infections | Phase 2 | AML (Acute Myelogenous Leukemia) | - | - |
All-trans retinoic acid | Phase 2 | Glioma | - | - |
Conditioning Regimen A | Phase 2 | AML (Acute Myelogenous Leukemia) | - | - |
Conditioning Regimen E | Phase 2 | AML (Acute Myelogenous Leukemia) | - | - |
BCR-ABL Tyrosine Kinase Inhibitor (TKI) | Phase 2 | Chronic Phase Chronic Myeloid Leukemia | - | - |
Post-transplant Ruxolitinib | Phase 2 | AML (Acute Myelogenous Leukemia) | - | - |
Conditioning Regimen B | Phase 2 | AML (Acute Myelogenous Leukemia) | - | - |
PTCy (D3, D4) | Phase 2 | AML (Acute Myelogenous Leukemia) | - | - |
Conditioning Regimen C | Phase 2 | AML (Acute Myelogenous Leukemia) | - | - |
Conditioning Regimen D | Phase 2 | AML (Acute Myelogenous Leukemia) | - | - |
Post-transplant Tacrolimus | Phase 2 | AML (Acute Myelogenous Leukemia) | - | - |
Supportive Care: Growth Factors | Phase 2 | AML (Acute Myelogenous Leukemia) | - | - |
INCA000585 | Phase 2 | Immune Thrombocytopenia | - | - |
INCB024360 | Phase 2 | Myelodysplastic Syndromes | - | - |
INCMGA00012 (PD-1 antibody) | Phase 2 | Pancreatic Cancer Non-resectable | - | - |
Yescarta | Phase 2 | Cytokine Release Syndrome | - | - |
MELITAC 12.1 Peptide Vaccine | Phase 2 | Mucosal Melanoma | - | - |
INCAGN01876 | Phase 2 | Advanced Malignancies | - | - |
GVAX Pancreas Vaccine | Phase 2 | Metastatic Pancreatic Adenocarcinoma | - | - |
INCAGN01949 | Phase 2 | Advanced Malignancies | - | - |
R-CHOP | Phase 2 | Non Hodgkins Lymphoma | - | - |
Pelareorep | Phase 2 | Anatomic Stage IV Breast Cancer AJCC v8 | - | - |
Ulixertinib | Phase 2 | Myelofibrosis | - | - |
Axatilimab (SNDX-6352) | Phase 2 | Myelofibrosis (MF) | - | - |
INCMGA00012 | Phase 2 | Resectable Sarcoma | - | - |
SRS | Phase 2 | Glioblastoma | - | - |
Tuparstobart | Phase 2 | Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8 | - | - |
Donor Lymphocyte Infusion (DLI) | Phase 2 | Acute Myeloid Leukemia | - | - |
Verzistobart | Phase 2 | Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8 | - | - |
Dovonex® calcipotriene | Phase 2 | Psoriasis | - | - |
Ruxolitinib Topical Cream | Phase 2 | Exanthema | - | - |
Pegaspargase | Phase 2 | Leukemia | - | - |
Vincristine Sulfate | Phase 2 | Leukemia | - | - |
Diprolene® AF betamethasone dipropionate cream | Phase 2 | Psoriasis | - | - |
Myeloablative conditioning regimen | Phase 2 | Leukemia | - | - |
CAPOX chemotherapy | Phase 2 | Rectal Cancer | - | - |
FOLFOX chemotherapy | Phase 2 | Rectal Cancer | - | - |
parsaclisib + ruxolitinib | Phase 2 | B-Cell Malignancies | - | - |
parsaclisib + ibrutinib | Phase 2 | B-Cell Malignancies | - | - |
Epcoritamab, tafasitamab and lenalidomide | Phase 2 | Large B Cell Lymphoma | - | - |
Granulocyte Colony-Stimulating Factor | Phase 2 | Aplastic Anemia | - | - |
JAK Inhibitor | Phase 2 | Myelodysplastic/Myeloproliferative Neoplasm | - | - |
topical ruxolitinib | Phase 2 | Pyoderma Gangrenosum | - | - |
Chimeric antigen receptor (CAR) T-cell therapy | Phase 2 | Diffuse Large B Cell Lymphoma | - | - |
INCB001158 | Phase 2 | Biliary Tract Cancer (BTC) | - | - |
INCB177054 | Phase 2 | Solid Tumors | - | - |
ICS-LABA | Phase 2 | Moderate to Severe Asthma | - | - |
Pemigatinib | Phase 2 | Non-Small Cell Lung Cancer (NSCLC) | - | Patent 2040 |
Asparaginase Erwinia Chrysanthemi | Phase 2 | Leukemia | - | - |
INCB013739 | Phase 2 | Type 2 Diabetes | - | - |
INCB000928 | Phase 2 | Anemia | - | - |
Ruxolitinib phosphate cream | Phase 2 | Psoriasis | - | Patent 2041 |
INCB054707 | Phase 2 | Hidradenitis Suppurativa | - | - |
Parsaclisib | Phase 2 | B-Cell Malignancies | - | - |
Ponatinib | Phase 2 | Philadelphia Positive | - | - |
INCB009471 | Phase 2 | HIV Infections | - | - |
INCB099280 | Phase 2 | Advanced Solid Tumor | - | - |
INCAGN02385 | Phase 2 | Endometrial Cancer | - | - |
Axatilimab | Phase 2 | Chronic Graft-versus-host-disease | - | - |
INCAGN02390 | Phase 2 | Melanoma | - | - |
Best available Treatment (BAT) | Phase 2 | Chronic Graft-versus-host-disease | - | - |
INCB018424 | Phase 2 | Rheumatoid Arthritis | - | - |
INCB028050 | Phase 2 | Rheumatoid Arthritis | - | - |
Prednisone or methylprednisolone | Phase 2 | Graft-versus-host Disease (GVHD) | - | - |
Ruxolitinib Phosphate | Phase 2 | Psoriasis | - | - |
Immune effector cell therapy | Phase 2 | Cytokine Release Syndrome | - | - |
Platinum-based chemotherapy | Phase 2 | Lung Cancer | - | - |
parsaclisib + itacitinib | Phase 2 | B-Cell Malignancies | - | - |
MEDI4736 | Phase 2 | Solid Tumors | - | - |
Regorafenib | Phase 2 | Pancreatic Cancer | - | - |
MK-3475 | Phase 2 | Microsatellite-instability (MSI) High Colorectal Cancer (CRC) | - | - |
Post-transplant Mycophenolate mofetil | Phase 2 | AML (Acute Myelogenous Leukemia) | - | - |
Chronic Graft-versus-host-disease
3 drugs in this indication
Melanoma
2 drugs in this indication
Graft-versus-host Disease (GVHD)
2 drugs in this indication
Hidradenitis Suppurativa
2 drugs in this indication
Polycythemia Vera
2 drugs in this indication
MPN (Myeloproliferative Neoplasms)
2 drugs in this indication
Nonsegmental Vitiligo With Genital Involvement
1 drug in this indication
Atopic Dermatitis
1 drug in this indication
Leukemia
1 drug in this indication
HIV Infections
1 drug in this indication
immune-resistant RCC
1 drug in this indication
Philadelphia Positive
1 drug in this indication
Solid Tumors
1 drug in this indication
Non-Small Cell Lung Cancer (NSCLC)
1 drug in this indication
Prurigo Nodularis
1 drug in this indication
Psoriasis
1 drug in this indication
Metastatic Merkel Cell Carcinoma
1 drug in this indication
Non-segmental Vitiligo
1 drug in this indication
Multiple Myeloma
1 drug in this indication
B-Cell Malignancies
1 drug in this indication
Diffuse Large B Cell Lymphoma
1 drug in this indication
Anemia
1 drug in this indication
Ovarian Cancer
1 drug in this indication
Advanced Solid Tumor
1 drug in this indication
NonSegmental Vitiligo
1 drug in this indication
Biliary Tract Cancer (BTC)
1 drug in this indication
Moderate to Severe Asthma
1 drug in this indication
Endometrial Cancer
1 drug in this indication
essential thrombocythemia
1 drug in this indication
Type 2 Diabetes
1 drug in this indication
rare bone disorder
1 drug in this indication
Fibrodysplasia Ossificans Progressiva
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Incyte Corporation's drug pipeline?→
CatalystAlert tracks 103 drug candidates in Incyte Corporation's (INCY) pipeline across Phase 3, Phase 2. Its lead program is Ruxolitinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Incyte Corporation's next FDA catalyst?→
Incyte Corporation's (INCY) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track INCY biotech catalysts?→
Add INCY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Incyte Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
